| Southern Oregon Foot & Ankle, Llc | |
|
1904 E Barnett Rd, Medford, OR 97504-8262 | |
| (541) 776-3338 | |
| (541) 776-4979 |
| Full Name | Southern Oregon Foot & Ankle, Llc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot Surgery |
| Location | 1904 E Barnett Rd, Medford, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891980546 | NPI | - | NPPES |
| 243148 | Medicaid | OR | |
| 891269000 | Other | OR | BLUE CROSS GROUP # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | (* (Not Available)) | Primary |
| Provider Name | Evan C Merrill |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1528166485 PECOS PAC ID: 4082603147 Enrollment ID: I20071004000253 |
News Archive
Federal legislation on health care reform and coverage expansion will have major impacts on cancer care. Community oncology professionals need to know how this legislation impacts them and their community practice. US Oncology, Inc., supporting the nation's foremost cancer treatment and research network, announced today that it will host a complimentary educational webinar for community-based oncology practices to discover how this new legislation will impact cancer care in 2010.
Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.
PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.
A new paper published on the preprint server medRxiv* in May 2020 suggests that India could be facing the end of a relatively mild outbreak of COVID-19 compared with many other countries.
Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.
› Verified 6 days ago
| Provider Name | Adam Gerber |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1780029231 PECOS PAC ID: 7517194806 Enrollment ID: I20160607000122 |
News Archive
Federal legislation on health care reform and coverage expansion will have major impacts on cancer care. Community oncology professionals need to know how this legislation impacts them and their community practice. US Oncology, Inc., supporting the nation's foremost cancer treatment and research network, announced today that it will host a complimentary educational webinar for community-based oncology practices to discover how this new legislation will impact cancer care in 2010.
Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.
PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.
A new paper published on the preprint server medRxiv* in May 2020 suggests that India could be facing the end of a relatively mild outbreak of COVID-19 compared with many other countries.
Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.
› Verified 6 days ago
| Provider Name | Devin Gardner Dimond |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1134521750 PECOS PAC ID: 6305193749 Enrollment ID: I20200827001411 |
News Archive
Federal legislation on health care reform and coverage expansion will have major impacts on cancer care. Community oncology professionals need to know how this legislation impacts them and their community practice. US Oncology, Inc., supporting the nation's foremost cancer treatment and research network, announced today that it will host a complimentary educational webinar for community-based oncology practices to discover how this new legislation will impact cancer care in 2010.
Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.
PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.
A new paper published on the preprint server medRxiv* in May 2020 suggests that India could be facing the end of a relatively mild outbreak of COVID-19 compared with many other countries.
Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Southern Oregon Foot & Ankle, Llc 1904 E Barnett Rd, Medford, OR 97504-8262 Ph: (541) 776-3338 | Southern Oregon Foot & Ankle, Llc 1904 E Barnett Rd, Medford, OR 97504-8262 Ph: (541) 776-3338 |
News Archive
Federal legislation on health care reform and coverage expansion will have major impacts on cancer care. Community oncology professionals need to know how this legislation impacts them and their community practice. US Oncology, Inc., supporting the nation's foremost cancer treatment and research network, announced today that it will host a complimentary educational webinar for community-based oncology practices to discover how this new legislation will impact cancer care in 2010.
Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.
PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.
A new paper published on the preprint server medRxiv* in May 2020 suggests that India could be facing the end of a relatively mild outbreak of COVID-19 compared with many other countries.
Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.
› Verified 6 days ago
Dr. Heather Aileen Holdermann, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 490 Murphy Rd, Medford, OR 97504 Phone: 541-779-5227 Fax: 541-779-1938 | |
Devin Dimond, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1904 E Barnett Rd, Medford, OR 97504 Phone: 541-776-3338 Fax: 541-776-4979 | |
Dr. Ricky Edward Mcclure, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 713 Golf View Drive, Medford, OR 97504 Phone: 541-770-1225 Fax: 541-770-1245 | |
Dpmbeckmannnror Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 835 Crater Lake Ave, Medford, OR 97504 Phone: 541-773-7717 | |
Rogue Valley Foot Clinic P.c. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2655 Siskiyou Blvd, Medford, OR 97504 Phone: 541-773-3338 Fax: 541-772-9526 | |
Dr. Lawrence F Helton, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 761 Golf View Dr, Ste A, Medford, OR 97504 Phone: 541-779-5263 Fax: 541-779-0555 | |
Evan Chard Merrill, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1904 E Barnett Rd, Medford, OR 97504 Phone: 541-776-3338 Fax: 541-776-4979 |